Loading…
Theriva Biologics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.8% over 5Y.
today you would have $1.92▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.21 | $1.75 | $10.75 | $11.25 | $67.50 | $95.00 | $127.50 | $140.00 | $4,462.50 | $6,650.00 | $20,037.50 | $12,775.00 | $13,387.50 | $15,400.00 | $11,025.00 | $10,937.50 | |
| P/S |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VTGNVistagen Therapeutics, Inc. | $0.25 | — | 0.5x | — | -166.46% | $11.22M |
| MTVAMetaVia Inc. | $1.70 | — | 1.6x | — | -175.68% | $11.2M |
| ADGMAdagio Medical Holdings, Inc. | $0.51 | — | — | — | -657.76% | $11.35M |
| BLRXBioLineRx Ltd. | $2.60 |
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 11.2x |
| P/B | 5.3x | 0.6x | 0.3x | 0.2x | 0.1x | 0.7x | — | 4.7x | 0.5x | — | 23.2x | 13.0x | 11.1x | 5.9x | 6.0x | 5.8x | 8.2x |
| EPS | -$2.08 | -$19.03 | -$28.48 | -$32.75 | -$47.50 | -$165.00 | -$245.00 | -$1,015.00 | -$1,557.50 | -$2,537.50 | -$4,725.00 | -$2,800.00 | -$2,362.50 | -$4,287.50 | -$2,537.50 | -$700.00 |
| Profit margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -65.46% |
| ROE | -123.23% | -154.32% | -134.54% | -49.64% | -37.98% | -21.81% | — | -840.36% | -78.32% | — | -708.84% | -272.49% | -207.03% | -80.87% | -131.01% | -115.44% | -47.81% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.7x |
| — |
| -46.72% |
| $11.36M |
| KPRXKiora Pharmaceuticals Inc | $2.62 | — | 0.8x | — | -56.37% | $11.59M |
| GDTCCytoMed Therapeutics Ltd | $0.92 | — | 2.1x | — | -50.28% | $10.89M |